Document Type : Case Study


1 RayaaGen Accelerator Director, Tehran, Iran.

2 Reference health laboratory, Ministry of health and medical education


We present a Non-Small Cell Lung Cancer Grade IV patient, diagnosed at 46 years of age, with multiple relapse from the diagnosis and demonstrating a poor prognosis after 3 cycles of treatments. A clinical comprehensive genomic profile was performed with the goal of finding potential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a combination chemotherapy determined by the molecular profiling, which would otherwise not have been considered. The mentioned approach was conducted since no other targeted therapies seemed actionable for him.


1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer
Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers
in 185 Countries. CA Cancer J Clin 2021; 71:209.
2.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer
Statistics, 2021. CA Cancer J Clin 2021; 71:7.
3.Howlader N, Forjaz G, Mooradian MJ, et al. The
Effect of Advances in Lung-Cancer Treatment on
Population Mortality. N Engl J Med 2020; 383:640.
4.Ann Oncol 2020 Jun;31(6):789-797. doi: 10.1016/j.
annonc.2020.03.293. Epub 2020 Mar 30.